22 F. Lauria & F. Forconi
18. Lauria F, Lenoci M, Annino L, et al. Efficacy of anti- treatment in a case of multi-resistant hairy cell leukemia. Leuk
CD20 monoclonal antibodies (Mabthera) in patients with Lymphoma 2007;48:2441–2443.
progressed hairy cell leukemia. Haematologica 2001;86:1046– 25. Sasaki M, Sugimoto K, Mori T, et al. Effective treatment of a
1050. refractory hairy cell leukemia variant with splenic pre-
19. Thomas DA, O’brien S, Bueso-Ramos C, et al. Rituximab in irradiation and alemtuzumab. Acta Haematol 2008;119:48–
relapsed or refractory hairy cell leukemia. Blood 2003;102: 53.
3906–3911. 26. Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy
20. Dearden C, Else M. Hairy cell leukemia. Curr Oncol Rep cell leukemia with purine analogs: a report of 219 patients with
2006;8:337–342. a median follow-up of 12.5 years. Cancer 2005;104:2442–
21. Else M, Dearden CE, Matutes E, et al. Long-term follow-up 2448.
of 233 patients with hairy cell leukaemia, treated initially with 27. Grever M, Kopecky K, Foucar MK, et al. Randomized
pentostatin or cladribine, at a median of 16 years from comparison of pentostatin versus interferon alfa-2a in pre-
diagnosis. Br J Haematol 2009;145:733–740. viously untreated patients with hairy cell leukemia: an
22. Forconi F, Sozzi E, Raspadori D, et al. Hairy cell leukemias intergroup study. J Clin Oncol 1995;13:974–982.
(HCL) with unmutated V-genes have a poorer response to 28. Lauria F, Bagnara GP, Catani L, et al. The inhibitory effect of
single agent 2CdA than HCL with mutated V-genes. Blood serum from hairy-cell leukaemia patients on normal progeni-
(Suppl) 2006;108:2327(Abstract). tor cells may disappear following prolonged treatment with
23. Kreitman RJ. Immunotoxins for targeted cancer therapy. alpha-interferon. Br J Haematol 1989;72:497–501.
AAPS J 2006;8:E532–E551. 29. Lauria F, Foa R, Gobbi M, et al. T lymphocyte subsets and
24. Forconi F, Toraldo F, Sozzi E, et al. Complete molecular colony growth in hairy-cell leukemia. Ric Clin Lab 1982;
remission induced by concomitant cladribine – rituximab 12:567–572.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46